The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global scaffold technology market is expected to exhibit a CAGR of 11.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Scaffold technology is used for controlling cell behavior in tissue engineering (TE) by mimicking the extracellular matrix (ECM) of the target tissue. TE combines the cells and highly porous scaffold biomaterials, such as polymers and ceramics, to regenerate damaged tissues of impaired organs. The available methods for fabricating these scaffold biomaterials include electrospinning, gas foaming, freeze-drying, Thermally Induced Phase Separation (TIPS), and solvent casting and particle leaching. Presently, a considerable rise in the incidences of diseases, injuries and congenital disabilities that lead to damaged tissues and organs is escalating the demand for scaffold technologies in surgical procedures across the globe.
Scaffold technology is manufactured using stereolithography, fused deposition modeling (FDM), selective laser sintering, and three-dimensional (3D) printing. It is utilized as cellular systems in tissue repairing on account of its biocompatibility and nontoxicity. This is among the key factors increasing the adoption of scaffold technology in drug screening and target validation of therapeutics. Additionally, the growing emphasis on improving transplantation processes is bolstering the market growth. Apart from this, numerous studies report organ damages in many patients diagnosed with coronavirus disease (COVID-19). Consequently, health professionals worldwide are relying on suitable scaffold biomaterials for tissue damage via TE approaches. Moreover, the ongoing research on using cartilage TE as a model system for overcoming the limitation of oxygen supply to cells is anticipated to expand the application of scaffold technology in engineering large organs for cardiac muscles and bones.
IMARC Group provides an analysis of the key trends in each sub-segment of the global scaffold technology market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, application, disease type and end user.
Breakup by Type:
Breakup by Application:
Breakup by Disease Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3D Biotek LLC, Akron Biotechnology LLC, Avacta Life Sciences Limited, Becton Dickinson and Company, Corning Incorporated, Medtronic Plc, Merck KGaA, Molecular Matrix Inc., Nanofiber Solutions LLC, NuVasive Inc., REPROCELL USA Inc., Tecan Trading AG and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Application, Disease Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||3D Biotek LLC, Akron Biotechnology LLC, Avacta Life Sciences Limited, Becton Dickinson and Company, Corning Incorporated, Medtronic Plc, Merck KGaA, Molecular Matrix Inc., Nanofiber Solutions LLC, NuVasive Inc., REPROCELL USA Inc., Tecan Trading AG and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at